Advancing drug development in myelodysplastic syndromes

Advancing drug development in myelodysplastic syndromes

Abstract: Myelodysplastic syndromes/neoplasms (MDSs) are heterogeneous stem cell malignancies characterized by poor prognosis and no curative therapies outside of allogeneic hematopoietic stem cell transplantation. Despite some recent approvals by the US Food and Drug Administration, (eg, luspaterce...

Full description

Saved in:
Bibliographic Details
Main Authors: Alain Mina, Kathy L. McGraw, Lea Cunningham, Nina Kim, Emily Y. Jen, Katherine R. Calvo, Lori A. Ehrlich, Peter D. Aplan, Guillermo Garcia-Manero, James M. Foran, Jacqueline S. Garcia, Amer M. Zeidan, Amy E. DeZern, Rami Komrokji, Mikkael A. Sekeres, Bart Scott, Rena Buckstein, Sara Tinsley-Vance, Amit Verma, Tanya Wroblewski, Steven Pavletic, Kelly Norsworthy
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952924007511
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items